Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice.

ABSTRACT:

Background

This study aimed to determine the incidence of pelvic fistulas in cervical cancer patients treated with bevacizumab in Japanese clinical practice.

Methods

A post-marketing surveillance (PMS) study was conducted between June 2016 and February 2018 to survey physicians who treated advanced or recurrent cervical cancer patients with bevacizumab (according to the product label). The clinical/treatment status of patients with pelvic fistulas was assessed in an additional retrospective case series study.

Results

142 patients were included in the PMS study (median age 51 years; 66.9% squamous cell carcinoma; 66.2% recurrent cervical cancer; 64.1% previous radiotherapy). Patients received a median of seven bevacizumab doses. Six patients, all of whom had a history

SUBMITTER: Sugiyama T 

PROVIDER: S-EPMC9393147 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature